

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number
WO 03/060072 A2

(51) International Patent Classification⁷:

C12N

(21) International Application Number: PCT/US02/40913

(22) International Filing Date:

20 December 2002 (20.12.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/343,315 21 December 2001 (21.12.2001) US

(71) Applicant (for all designated States except US): IMMUNEX CORPORATION [US/US]; Law Department, 51 University Street, Seattle, WA 98101 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



(72) Inventor; and

(75) Inventor/Applicant (for US only): REDDY, Pranitha [US/US]; 6811 18th Avenue NE, Seattle, WA 98115 (US).

(74) Agents: ODRE, Steven, M. et al.; Immunex Corporation, Law Department, 51 University Street, Seattle, WA 98101 (US).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/060072 A2

(54) Title: RECOMBINANT POLYPEPTIDES

(57) Abstract: The present invention relates, in part, to a polypeptide domain having reduced immunogenicity that is capable of inducing trimers in heterologous polypeptides, fusion polypeptides comprising the trimer inducing domain, nucleic acids encoding the polypeptides of the invention and methods of making and using the same.

RECOMBINANT POLYPEPTIDES

This application claims the benefit of U. S. Provisional Application No. 60/343,315, filed December 21, 2001 which is hereby incorporated by reference.

5

INTRODUCTION

The present invention is directed, in part, to compositions relating to polypeptide domains having reduced immunogenicity that are capable of inducing trimers in heterologous polypeptides, fusion polypeptides comprising such trimer inducing domains, 10 nucleic acids encoding the polypeptides of the invention, and methods of making and using the same.

BACKGROUND

The structure of a polypeptide is an important element in its activity. Oftentimes, 15 a properly folded polypeptide needs to associate with itself or different polypeptides in order to be active. Most often these interactions are as homodimers and provide an active complex, however, heterotrimers also occur. Defined trimerizing motifs are typically coiled coil domains (Burkhard et al., 2001, Trends in Cell Biol., 11:82), and includes SP-D trimerizing domains (U.S. Patent Nos. 5,716,805 and 6,190,886).

20 Although lacking a distinctive coiled coil motif, additional molecules known to require trimerization for optimal activity include the tumor necrosis factor super family, such as TNF-alpha, lymphotoxin alpha, and CD40L (TNFSF5), among others. Without trimerization, many TNF super family polypeptides have low or absent activity (Fanslow et al., (1994) Seminars Immunology, 6:267-278). CD40 is a transmembrane 25 polypeptide member of the tumor necrosis factor receptor super family and is involved in stimulating proliferation and differentiation of humoral and cellular immune cells. In particular, CD40 is involved in isotype switching and is important in T-cell activation and production of type 1 cytokines in response to protein antigens (Noelle, R, (1996) Immunity, 4:415; and Borrow et al., (1996) J. Exp. Med., 183:2129).

30 It has been shown that CD40L (TNFSF5) is normally active in a membrane bound form, however, this form is difficult to administer as a therapeutic. The soluble version of

CD40L (TNFSF5) was found to have very little stimulatory activity, but by trimerizing soluble CD40L (TNFSF5) using a mutated GCN4 leucine zipper domain, significant activation of target cells was achieved (Fanslow et al., (1994) *Seminars Immunology*, 6:267-278; Morris et al., (1999) *J. Biol. Chem.*, 274:418-423; U.S. Patent No. 5,716,805).

5 A significant limitation of using the mutant leucine zipper trimerizing domain in a therapeutic fusion polypeptide is that leucine zippers are typically nuclear proteins, *i.e.*, intracellular. Thus even though the polypeptide may be of the same species as a subject being treated with the polypeptide, having not been seen by the immune system can lead to the polypeptide being recognized as foreign when expressed extracellularly and
10 triggering an immune response in the subject. This response is particularly deleterious to the continuous or long-term administration of the fusion polypeptide to a patient. The present invention addresses this issue by providing polypeptide domains that will have reduced immunogenicity in addition to having trimerization properties.

15

SUMMARY OF THE INVENTION

The present invention relates, in part, to a polypeptide that is capable of inducing trimerization when fused to a heterologous polypeptide, fusion polypeptides comprising the trimerizing domain, nucleic acids encoding the polypeptides of the invention and methods of making and using the same. More particularly, the present invention is
20 directed to a fusion polypeptide comprising a first polypeptide capable of forming a trimer fused to a second heterologous polypeptide having a desired biological activity. It is also contemplated that the fusion of a first polypeptide capable of forming a trimer and a second polypeptide heterologous to the first polypeptide results in an increase in the biological activity of the second polypeptide when compared to the activity of a monomer
25 of the second polypeptide.

In one aspect, the invention encompasses a fusion polypeptide comprising a first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID NO:10, wherein x is 110 to 154 and y is 201 to 270 fused to a second heterologous polypeptide, and wherein the fusion polypeptide is capable of forming a trimer.

30

In another aspect, the invention encompasses a fusion polypeptide comprising a first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID

NO:10, wherein x is 110 to 173 and y is 179 to 270, fused to a heterologous polypeptide, and wherein the fusion polypeptide is capable of forming a trimer.

In another aspect, the invention encompasses a fusion polypeptide comprising a first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID 5 NO:10, wherein x is 110 to 154 and y is 201 to 270, with at least one substitution of an amino acid, wherein the first polypeptide is at least 80% identical to the polypeptide depicted in SEQ ID NO:10, and wherein said first polypeptide is fused to a second heterologous polypeptide, wherein the ability to trimerize is retained.

In another aspect, the invention encompasses a polypeptide domain comprising a 10 first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID NO:10, wherein x is 110 to 173 and y is 179 to 270, with at least one substitution of an amino acid, wherein the first polypeptide is at least 80% identical to the polypeptide depicted in SEQ ID NO:10, wherein the ability to trimerize is retained, and wherein the first polypeptide is fused to a second heterologous polypeptide.

15 In yet another aspect, the invention relates to a fusion polypeptide comprising amino acids 154 to 203 of the polypeptide depicted in SEQ ID NO:10, or alternatively, the invention relates to a fusion polypeptide comprising amino acids 120 to 180 of the polypeptide depicted in SEQ ID NO:10.

The invention further contemplates that the polypeptide capable of forming trimer, 20 as described above and throughout the current specification, has at least three heptad repeats. However, it is understood that the trimerization polypeptide can have four heptad repeats, five heptad repeats, six heptad repeats, seven heptad repeats or more as desired by the ordinarily skilled artisan.

In still another aspect, the invention encompasses nucleic acids encoding the 25 polypeptides of the invention. Methods of making recombinant vectors comprising the nucleic acids of the invention are also within the scope of the invention. In yet another aspect, the polypeptides encoded by the nucleic acid molecules of the invention are non-immunogenic in a subject to which they are administered.

In addition, it is contemplated that the nucleic acids of the invention can be 30 transfected in host cells to produce recombinant polypeptides. In another aspect, the invention encompasses a method of producing a polypeptide encoded by the nucleic acid of the invention, comprising the steps of growing a host cell transfected with nucleic

acids of the invention in conditions favorable for expression of the polypeptide, and optionally isolating said polypeptide.

In yet another aspect, the invention encompasses a method of constructing a recombinant expression vector comprising the steps of linking a first nucleic acid 5 comprising nucleotides x to y of the nucleic acid depicted in SEQ ID NO:9, wherein x is nucleotides 331 to 460, and y nucleotides is 601 to 808, and a second nucleic acid encoding a heterologous polypeptide to the first nucleic acid into a compatible cloning site of an expression vector, followed by amplifying and isolating said recombinant expression vector.

10 In still another aspect, the invention encompasses a method of constructing a recombinant expression vector comprising the steps of linking a first nucleic acid comprising nucleotides x to y of the nucleic acid depicted in SEQ ID NO:9, wherein x is nucleotides 331 to 508, and y nucleotides is 546 to 808, and a second nucleic acid encoding a heterologous polypeptide to the first nucleic acid into a compatible cloning 15 site of an expression vector, followed by amplifying and isolating said recombinant expression vector.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1. Nucleic acids of the oligonucleotides utilized for construction of a 20 polynucleotide encoding a macrophage scavenger receptor-CD40L (TNFSF5) fusion polypeptide (sequence 34 is SEQ ID NO:1, sequence 33 is SEQ ID NO:2, sequence 32 is SEQ ID NO:3 and sequence 35 is SEQ ID NO:4).

Figures 2A-B. Figure 2A depicts the nucleic acid sequence (SEQ ID NO:5) 25 encoding the IL2 secretion peptide fused to the scavenger receptor trimerization domain, which is fused to a receptor binding domain of the CD40L (TNFSF5). The fusion polypeptide encoded by the nucleic acid is depicted as SEQ ID NO:6. Figure 2B depicts the nucleic acid sequence (SEQ ID NO:7) encoding the human growth hormone secretion peptide fused to the scavenger receptor trimerization domain, which is fused to a receptor binding domain of the CD40L (TNFSF5). The fusion polypeptide encoded by the nucleic 30 acid is depicted as (SEQ ID NO:8).

Figure 3 depicts a western blot demonstrating expression of the CD40L (TNFSF5) fusion polypeptide. Arrows indicate the location in the gel of the fusion polypeptide.

Lanes 1 and 2 are control using the isoleucine-CD40L (TNFSF5) trimerizing polypeptide, and lanes 3-6 are scavenger receptor trimerization domains fused to the receptor binding domain of CD40L (TNFSF5).

Figure 4. The coding region of the nucleic acid (SEQ ID NO:9) encoding the 5 human macrophage scavenger receptor A is depicted including the encoded polypeptide (SEQ ID NO:10).

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates, in part, to a polypeptide domain capable of inducing 10 trimers in heterologous polypeptides, fusion polypeptides comprising the trimer inducing domain, nucleic acids encoding the polypeptides, and methods of making and using the polypeptides.

In one embodiment, the invention relates to a portion of the extracellular domain 15 of the macrophage scavenger receptor (SR-A) polypeptide corresponding to a coiled coil region, *i.e.*, the trimerization domain. The coiled coil region of the SR-A has trimerizing properties (Frank et al., 2000, *J. Biol. Chem.*, 275:11672-11677). As such, this domain is useful in the present invention to provide a trimerizing domain, with no or reduced immunogenicity, fused to a heterologous polypeptide.

Thus, in one embodiment, the invention relates to a fusion polypeptide comprising 20 a first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID NO:10, wherein x is 110 to 154 and y is 201 to 270 fused to a second heterologous polypeptide. In another embodiment, the invention relates to a fusion polypeptide comprising a portion of the SR-A polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID NO:10, wherein x is 110 to 173 and y is 179 to 270 fused 25 to a second heterologous polypeptide.

In a particular embodiment, the invention relates to a fusion polypeptide comprising amino acids 154 to 203 of the polypeptide depicted in SEQ ID NO:10 fused to a second heterologous polypeptide. In another particular embodiment, the invention relates to a fusion polypeptide comprising amino acids 120 to 180 of the polypeptide 30 depicted in SEQ ID NO:10 fused to a second heterologous polypeptide.

In another embodiment, the invention relates to a fusion polypeptide comprising a first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID

NO:10, wherein x is 110 to 154 and y is 201 to 270, with at least one substitution of an amino acid, wherein the first polypeptide is at least 80% identical to the polypeptide depicted in SEQ ID NO:10, wherein the ability to trimerize is retained, and wherein said first polypeptide is fused to a second heterologous polypeptide. And in yet another 5 embodiment, the invention relates to a fusion polypeptide comprising a first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID NO:10, wherein x is 110 to 173 and y is 179 to 270, with at least one substitution of an amino acid, wherein the first polypeptide is at least 80% identical to the polypeptide depicted in SEQ ID NO:10, wherein the ability to trimerize is retained, and wherein said first polypeptide is 10 fused to a second heterologous polypeptide.

In another embodiment, the invention relates to a fusion polypeptide comprising a first polypeptide consisting of amino acids 154 to 203 of the polypeptide depicted in SEQ ID NO:10, with at least one substitution of an amino acid, wherein the first polypeptide is at least 80% identical to the polypeptide depicted in SEQ ID NO:10, wherein the ability 15 to trimerize is retained, and wherein said first polypeptide is fused to a second heterologous polypeptide. In yet another embodiment, the invention relates to a fusion polypeptide comprising a first polypeptide consisting of amino acids 154 to 203 of the polypeptide depicted in SEQ ID NO:10, wherein said first polypeptide is fused to a second heterologous polypeptide.

20 In the above embodiments, the second heterologous polypeptide preferably has a desired biological activity. A biological activity, as will be understood by one of ordinary skill, can be defined as binding of a ligand to a receptor, binding of a receptor to a ligand, binding affinity of a immunoglobulin-like polypeptide to it's cognate antigen, or the like. Additionally, the biological activity may be an enzymatic activity.

25 In one embodiment, the fusion polypeptide the invention has reduced immunogenicity, and more preferably embodiment, the fusion polypeptide is non-immunogenic.

In one aspect, various species of macrophage scavenger receptor can serve as a trimerization motif for a fusion polypeptide, in particular, it is contemplated that bovine 30 (Genbank Accession No. X54183), murine (Genbank Accession No. L04275), human (Genbank Accession No. XM_005021), and/or simian scavenger receptor polypeptides can be used according to the teachings of the present invention. It is to be understood that

this is not an exhaustive listing and additional species' macrophage scavenger receptors are within the scope of the invention.

A consensus coiled coil polypeptide sequence, as it pertains to the invention, follows the basic pattern as set forth in Burkhard et al. (2001, Trends Cell Biol., 11:82).

5 The positions of amino acids in the heptad repeats are typically designated alphabetically as 'a.b.c.d.e.f.g.' Positions a and d are apolar residues and there is a strong preference for specific amino acids at these positions. An apolar residue is understood by one of skill in the art to include alanine, isoleucine, glycine, proline, leucine, methionine, phenylalanine, tryptophan, valine and tyrosine. Particular residues at each of these positions can

10 determine the nature of the secondary and tertiary structure of the coiled-coil *i.e.*, dimeric versus trimeric. Indeed, targeted mutation has been performed to redesign dimeric leucine zippers into the trimeric isoleucine zippers by mutation of residues in positions a and d (U.S. Patent No. 5,716,805).

Computer programs can be enlisted to assist in the identification of coiled coil polypeptides useful in the present invention. For example, FOLDER has been used to identify particular domains based on sequence identity (Srinivasan et al., (1993) Prot. Sci., 2:277-289) and can be used to identify or modify a coiled domain as used herein. Amino acids of CD40L (TNFSF5) were analyzed using folder program to study and predict trimerization propensity of several different heptad repeats within the CD40L (TNFSF5) coiled coil domains. Further, the multicoil program (Harbury et al., (1993) Science, 262:1401) can be used to confirm that a sequence, *i.e.*, a scavenger receptor sequence such as human, murine and bovine polypeptides, are coiled coils. This program finds particular utility when a native sequence is mutated to alter the properties of a polypeptide, such as, for example to increase trimerization and/or decrease

20 immunogenicity. Thus a mutant trimerizing polypeptide can be analyzed by computer program to determine whether it retains required characteristics.

In one embodiment, a trimerization polypeptide of the invention has at least 80% sequence identity (at least 85%, at least 90%, at least 95%, at least 97.5%, or at least 99%, and/or at least 99.5%) with a naturally occurring trimerizing polypeptide, *e.g.*, such as the polypeptide depicted in SEQ ID NO:10, such sequence identity being determined by comparing the amino acids of the polypeptides when aligned so as to maximize overlap and identity while minimizing sequence gaps. The percent identity of two amino acids or

two nucleic acids can be determined by visual inspection and mathematical calculation, or more preferably, the comparison is done by comparing sequence information using a computer program. An exemplary, preferred computer program is the Genetics Computer Group (GCG; Madison, WI) Wisconsin package version 10.0 program, 'GAP'

5 (Devereux et al., (1984) *Nucl. Acids Res.* 12: 387). The preferred default parameters for the 'GAP' program includes: (1) The GCG implementation of a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted amino acid comparison matrix of Gribskov and Burgess, *Nucl. Acids Res.* 14:6745, (1986) as described by Schwartz and Dayhoff, eds., (1979) *Atlas of Polypeptide*

10 *Sequence and Structure*, National Biomedical Research Foundation, pp. 353-358; or other comparable comparison matrices; (2) a penalty of 30 for each gap and an additional penalty of 1 for each symbol in each gap for amino acid sequences, or penalty of 50 for each gap and an additional penalty of 3 for each symbol in each gap for nucleotide sequences; (3) no penalty for end gaps; and (4) no maximum penalty for long gaps.

15 In one embodiment, a trimerization polypeptide of the invention comprises a sequence having at least 80% identity with amino acids x to y of the polypeptide depicted in SEQ ID NO:10, wherein x is 110 to 154 and y is 201 to 270. In another embodiment, the trimerization polypeptide of the invention comprises a sequence having at least 80% identity with amino acids x to y of the polypeptide depicted in SEQ ID NO:10, wherein x is 110 to 173 and y is 179 to 270.

20 Other programs used by those skilled in the art of sequence comparison can also be used, such as, for example, the BLASTN program version 2.0.9, available for use via the National Library of Medicine website www.ncbi.nlm.nih.gov/gorf/wblast2.cgi, or the UW-BLAST 2.0 algorithm. Standard default parameter settings for UW-BLAST 2.0 are described at the following Internet site: sapiens.wustl.edu/blast/blast/#Features. In addition, the BLAST algorithm uses the BLOSUM62 amino acid scoring matrix, and optional parameters that can be used are as follows: (A) inclusion of a filter to mask segments of the query sequence that have low compositional complexity (as determined by the SEG program of Wootton and Federhen (*Computers and Chemistry*, 1993); also see Wootton and Federhen, 1996, *Analysis of compositionally biased regions in sequence databases*, *Methods Enzymol.* 266: 554-71) or segments consisting of short-periodicity internal repeats (as determined by the XNU program of Claverie and States (*Computers*

and Chemistry, 1993)), and (B) a statistical significance threshold for reporting matches against database sequences, or E-score (the expected probability of matches being found merely by chance, according to the stochastic model of Karlin and Altschul (1990); if the statistical significance ascribed to a match is greater than this E-score threshold, the 5 match will not be reported.); preferred E-score threshold values are 0.5, or in order of increasing preference, 0.25, 0.1, 0.05, 0.01, 0.001, 0.0001, 1e-5, 1e-10, 1e-15, 1e-20, 1e-25, 1e-30, 1e-40, 1e-50, 1e-75, or 1e-100.

A trimerization domain can be fused to a heterologous polypeptide at the amino terminus, carboxyl terminus and/or or both. In addition, the trimerization domain can be 10 internal to the heterologous polypeptide. Regardless of the location of the fusion of the trimerization domain and the heterologous polypeptide, it is to be understood that the trimerizing domain retains its ability to induce trimers (homotrimers and/or heterotrimers), and the heterologous polypeptide also retains its biological activity.

As used herein, the term "fusion polypeptide" refers to a contiguous polypeptide 15 expressed from a single nucleic acid molecule, wherein the nucleic acid encodes in the same reading frame either two or more heterologous polypeptides, or domains of a polypeptide arranged in a nonnaturally occurring order. In addition to the polypeptides of the invention, other examples of fusion polypeptides include an Fc domain of an antibody or a leucine zipper domain fused to a soluble extracellular domain of a transmembrane 20 polypeptide, *e.g.*, CD40L (TNFSF5). WO 93/08207 and WO 96/40918 describe the preparation of oligomeric soluble forms of CD40L (TNFSF5), including an immunoglobulin fusion polypeptide and a mutated leucine zipper fusion polypeptide, respectively; the methods of constructing and assaying the products discussed therein are also applicable to the compositions of the present invention. The fusion of a trimerizing 25 domain to a heterologous polypeptide can also occur through a linker, such as an epitope tag, or a flexible linker that assists in structural formation.

It is to be understood that any portion of a polypeptide having a desired biological activity can be expressed as a fusion to the multimerizing polypeptides of the invention. Examples include but are not limited to transmembrane polypeptides, and non- 30 transmembrane polypeptides such as enzymes, hormones, and cytokines. In particular, it is contemplated that fusion polypeptides of GM-CSF, IL3, GM-CSF and IL3, M-CSF,

and members of the hematopoietin receptor family (Cosman, et al., (1990) Trends Biochem. Sci., 15:265). Homo and hetero oligomers are further contemplated.

Additional examples of heterologous polypeptides that can be trimerized include, but are not limited to the tumor necrosis factor super family, which are listed below.

5 Each pairing is listed first by the ligand followed by the corresponding receptor where a ligand may have more than one receptor. The nomenclature for the TNF family member symbols is as described in Locksley et al. (2001, Cell, 104:487:501), wherein a ligand is denoted by tumor necrosis factor super family (TNFSF) and receptors are denoted by tumor necrosis factor receptor super family (TNFRSF) in numerical order.

10 The symbol for the TNF family member ligand or receptor is first, followed by a Genbank Accession number in double parenthesis, which is followed by the various common names for the family member as applicable: TNFSF1 ((Genbank Accession No. X01393), TNFB, Lymphotoxin (LT)-alpha) and its receptor tumor necrosis factor receptor TNFRSF1A ((Genbank Accession No. M75866), TNF-R); TNFSF2 ((Genbank Accession No. X02910) tumor necrosis factor (TNF)) and its receptor TNFRSF1B ((Genbank Accession No. M32315) TNF-R); TNFSF3 ((Genbank Accession No. L11016) LT-beta) and its receptor TNFRSF3 ((Genbank Accession No. L04270) LTBR, TNFR2-RP, CD18, TNFR-RP, TNFCR, TNF-R-III); TNFSF4 ((Genbank Accession No. D90224) OX-40L) and its receptor TNFRSF4 ((Genbank Accession No. X75962) OX40); TNFSF5 ((Genbank Accession No. X67878) CD40L) and its receptor TNFRSF5 ((Genbank Accession No. X60592) CD40); TNFSF6 ((Genbank Accession No. U11821) FasL) and its receptors TNFRSF6 (Genbank Accession No. M67454) FAS, CD95) and TNFRSF6B ((Genbank Accession No. AF104419) DcR3); TNFSF7 ((Genbank Accession No. L08096) CD70, CD27L) and its receptor TNFRSF7 ((Genbank Accession No. M63928) CD27); TNFSF8 ((Genbank Accession No. L09753) CD30LG) and its receptor TNFRSF8 ((Genbank Accession No. M83554) CD30); TNFSF9 ((Genbank Accession No. U03398) 4-1BB-L) and its receptor TNFRSF9 ((Genbank Accession No. L12964) 4-1BB); TNFSF10 ((Genbank Accession No. U37518) TRAIL) and its receptors TNFRSF10A ((Genbank Accession No. U90875) DR4), TNFRSF10B ((Genbank Accession No. AF012628) DR5, KILLER, TRAIL-R2), TNFRSF10C ((Genbank Accession No. AF012536) DcR1, TRAILR3), and TNFRSF10D ((Genbank Accession No. AF029761) DcR2, TRAILR4); TNFSF11 ((Genbank Accession No. U03399) 4-1BB-R) and its receptor TNFRSF11 ((Genbank Accession No. L12965) TRAIL-R1).

Accession No. AF013171) RANKL, OPGL) and its receptors TNFRSF11A ((Genbank Accession No. AF018253 RANK) and TNFRSF11B (Genbank Accession No. U94332) OPG); TNFSF12 ((Genbank Accession No. AF030099) TWEAK) and its receptors TNFRSF12 ((Genbank Accession No. U72763) DR3, TRAMP) and TNFRSF12L (DR3L); TNFSF13 ((Genbank Accession No. NM_003808) APRIL) and its receptors TNFRSF13 and TNFSF13B ((Genbank Accession No. AF136293) THANK, BLYS); TNFSF14 ((Genbank Accession No. AF036581) LIGHT, LT-gamma, HVEM-L) and its receptor TNFRSF14 ((Genbank Accession No. U70321) HVEM, ATAR, TR2, LIGHTR, HVEA); TNFSF15 ((Genbank Accession No. AF039390) TL1, VEGI) and its receptor TNFRSF15; TNFSF16 and its receptor TNFRSF16 ((Genbank Accession No. M14764) nerve growth factor receptor (NGFR), p75NTR); TNFSF17 and its receptor TNFRSF17 ((Genbank Accession No. Z29574) BCMA); TNFSF18 ((Genbank Accession No. AF125303) AITRL TL6 hGITRL) and its receptor TNFRSF18 ((Genbank Accession No. AF125304) AITR, GITR); TNFSF19 and its receptor TNFRSF19 (Genbank Accession No. AF173166); TNFSF20 and its receptor TNFRSF20 (Locksley et al., 2001, Cell, 104:487:501). In a specific embodiment, a polypeptide that can be utilized as a heterologous polypeptide by the methods and compositions of the invention is CD40L (TNFSF5).

Additional polypeptides can be fused to the fusion polypeptide to facilitate purification such as, for example, epitope tags can be placed on the amino terminus, carboxyl terminus or internally. Well known epitope tags include, *e.g.*, histidine tag, FLAG tag, and GST among others. It is further contemplated that an epitope tag can be genetically engineered to include a proteolytic cleavage site between the tag and the rest of the polypeptide such that the epitope tag can be cleaved and removed from the fusion polypeptide. Examples of proteolytic enzymes known to recognize unique amino acids in polypeptides include Factor Xa and thrombin and are commercially available.

The invention contemplates higher order multimers of a fusion polypeptide of the invention, such that it has increased activity relative to a non-multimerized polypeptide. As used herein, a “multimer” or a “multimerized polypeptide” can include a dimer, trimer, tetramer, dimer of a trimer, trimer of a trimer, dimer of a tetramer, trimer of a tetramer and so on. Examples of additional multimerization domains can include leucine zippers or Fc domains. Accordingly, a polypeptide comprising a dimerizing domain,

(e.g., an Fc domain) and trimerizing domain (e.g., a scavenger receptor alpha trimerization domain) can induce a dimer of a trimer such that six polypeptides associate. It is further contemplated that these multimers can have bioactivity that is greater than monomers or lower order multimers. For example, it is contemplated that a trimer will 5 have higher activity than a dimer.

The terms "reduced immunogenicity" or "non-immunogenic" are understood to mean that a therapeutic, such as a polypeptide of the invention, fails to induce an appreciable immune response in a subject, preferably a human, to which it has been administered. An appreciable immune response is one that is measurable such that one of 10 ordinary skill in the art would recognize it as having been induced by the polypeptide of the invention. This definition excludes normal variations due to differences in reagents used in the assays, variability in the samples, or where there are otherwise imperfections in the testing procedures. An immune response can be measured by any variety of standard techniques, such as for example using an enzyme linked immunosorbent assay 15 (ELISA) to detect antibodies made in response to a therapeutic, by measuring cytokine production by the subject in appropriate time periods subsequent to administration of the polypeptide, and/or by measuring proliferation of particular immune cell types, among other well known methods.

One exemplary method of reducing or eliminating immunogenicity in a 20 therapeutic polypeptide, is to use polypeptides derived from the same species as will be treated. For example, when a polypeptide is to be administered to a human, the polypeptide should be human derived. If in this example human polypeptides are not available, the polypeptides can be humanized such that immunogenicity is reduced. Humanizing a polypeptide can be performed, for example, in a manner analogous to 25 humanizing antibodies, wherein a mouse antibody sequence is humanized by mutating individual amino acids to correspond to human polypeptide sequences such that the antibody does not induce a strong human anti-mouse response when administered.

Nucleic acids encoding the foregoing polypeptides are also within the scope of the invention. These nucleic acids can be cloned and mutated by well known techniques and 30 are commonly propagated in plasmids or other vectors (Sambrook et al. eds., (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Vectors can also include

additional components to facilitate replication in prokaryotic and/or eukaryotic cells, integration of the construct into a eukaryotic chromosome, and markers to aid in selection of and/or screening for cells containing the construct. Vectors of the invention are recombinant DNA vectors including, but not limited to, plasmids, phages, phagemids, 5 cosmids, viruses, retroviruses, and the like, which are used to insert heterologous polynucleotides into a cell.

As used herein, the term "linking" is understood to mean that two molecules are brought into proximity to one another by either an affinity interaction and/or a covalent attachment such as for example, ligation of nucleotides to one another in cloning, by 10 chemical cross-linking, or by some other similar method of linking. Nucleotides can be obtained from genomic, cDNA or vector sources and linked to heterologous nucleic acids by traditional digestion and ligation in cloning, or by amplification of desired portions of sequences during PCR, among other methods.

In one embodiment, a nucleic acid molecule encoding a fusion polypeptide of the 15 invention is operably linked to a heterologous control element. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid. Operably linked can also mean that two different nucleic acid molecules encoding different polypeptides have transcription induced simultaneously. In the case of operably linked nucleic acids, they can also be contiguous in a single transcriptional unit, while 20 translation is directed from one or more ribosomal start sites. In addition, operably linked can mean that two polypeptide coding regions can be joined in frame such that they encode a single contiguous polypeptide, *i.e.*, a fusion polypeptide.

An enhancer or silencer is operably linked to a nucleic acid when it is positioned relative to the nucleic acid in such a manner as to increase or decrease the transcription of 25 the nucleic acid. Enhancers and silencers can be located upstream, downstream or embedded within the coding regions of the nucleic acid.

Expression vectors can be for expression of a fusion polypeptide of the invention in prokaryotic (*e.g.*, *E. coli*) or eukaryotic cells (*e.g.*, insect cells (using baculovirus expression vectors), yeast cells, plant cells, or mammalian cells). Suitable host cells 30 include prokaryotic, eukaryotic and plant cells, and are discussed further in Goeddel, (1990) Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA. Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the protein expression.

Examples of suitable inducible *E. coli* expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., (1990) Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California 60-89).

5 In another embodiment, the expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYEpSec1 (Baldari et al., (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al. (1987) Gene 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and pPicZ (Invitrogen Corp, San Diego, CA). Alternatively, the 10 expression vector is a baculovirus expression vector such as, for example, the pAc series (Smith et al. (1983) Mol. Cell Biol. 3:2156-2165). In another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors are numerous and include but are not limited to pCDM8 (Seed (1987) Nature 329:840) and pMT2PC (Kaufman et al., (1987) EMBO J. 15 6:187-195).

20 A recombinant mammalian expression vector can also be designed such that it is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable 25 tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al., (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733), immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), and mammary gland-specific 25 promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166).

30 Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the

parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic (e.g., *E. coli*), eukaryotic cell (e.g., insect cells, yeast or mammalian cells) or plant cells.

Cells used in the invention can be genetically engineered to express a fusion 5 polypeptide of the invention. By genetically engineered is meant that the cell has been transfected, transformed or transduced with a recombinant polynucleotide molecule, and/or otherwise altered (e.g., by homologous recombination and gene activation) so as to cause the cell to express the fusion polypeptide. Methods and vectors for genetically engineering cells and/or cell lines are well known to those of skill in the art; for example, 10 various techniques are illustrated in *Current Protocols in Molecular Biology*, Ausubel et al., eds. (Wiley & Sons, New York, (1988) and quarterly updates) and Sambrook et al., (1989) *Molecular Cloning: A Laboratory Manual* (Cold Spring 15 Laboratory Press).

It is further contemplated that the fusion polypeptides of the invention can be 15 expressed in transgenic animals, such as for example, in mice, goats or cows. The latter example, the expression of the fusion polypeptide may be designed such that it is secreted into the animals milk. A transgenic animal can be produced by introducing the nucleic acid encoding a fusion polypeptide of the invention into a fertilized oocyte or an embryonic stem cell. Such host cells can then be used to create non-human transgenic 20 animals.

Vector DNA can be introduced into cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, 25 DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (supra), and other laboratory manuals. For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the transfected DNA into their genome. In order to 30 identify and select these integrants, a gene that encodes a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs,

such as G418, hygromycin and methotrexate. Cells stably transfected with the introduced nucleic acid can be identified by drug selection.

In another embodiment, fusion of a trimerization polypeptide of the invention to a second heterologous polypeptide that is a ligand can result in enhanced signaling through the ligand's receptor. While not meant to be limiting, the mechanism of this increase can occur by increased binding and activation of the receptor such that the receptor has increased biological activity. For example multimerized CD40L (TNFSF5) has been shown, when administered to a cell population, to enhance immune cell proliferation relative to untreated cells (see Example, below) and also to cells that are treated with non-10 multimerized CD40L (TNFSF5), thus according to the invention, when soluble CD40L (TNFSF5) is fused to a trimerization polypeptide of the invention domain it has increased activity relative to soluble CD40L (TNFSF5) that is not trimerized.

The terms "enhanced" or "increased" are understood to include any measurable elevation in biological activity as measured against an untreated control. An increase can 15 be 10%, 20%, 30%, 40% or more and increases can exceed 100% of the activity of controls. Examples of assays to measure increases include but are not limited to evaluating cytokine release, induction of surface molecule expression, increased or decreased cellular proliferation, increased or decreased apoptotic cell death, and biochemical activation, *e.g.*, phosphorylation patterns. In a particular example, addition 20 of trimerized CD40L (TNFSF5) to cells can result in inhibition of IL-4 induced IgE secretion or elevated expression of CD23 in mixed lymphocyte cultures. In a particular embodiment of the invention, multimers of trimers of the invention have activity that is higher than the activity of the non-multimerized trimers.

In yet another embodiment, fusion of a multimerization polypeptide, such as a 25 trimerization domain, to a second heterologous polypeptide that is a receptor can result in decreased signaling through the corresponding, native receptor. While not meant to be limiting, the mechanism of this reduction can occur by competitive binding of the soluble polypeptide with the receptor's ligand, wherein this binding prevents the ligand from activating the receptor. For example, administration of TNFR:Fc (*i.e.*, Etanercept), a 30 dimer, results in a reduction in the signaling through the TNF-alpha receptor relative to untreated cells as measured, in part, by reduced disease symptoms (Spencer-Green, 2000,

Ann. Rheum. Dis., 59 Suppl 1, pp. 46-9). Thus, a multimer of a TNFR according to the invention can inhibit TNF-alpha mediated inflammation.

The term "reduced" is understood to include any measurable decrease in biological activity as measured against an untreated control. More particularly, a 5 decrease can be 10%, 20% or more including up to an 100% reduction. Examples of assays to measure this reduction include but are not limited to increased or decreased cytokine release, induction of surface molecule expression, increased or decreased cellular proliferation, increased or decreased apoptotic cell death, and biochemical activation, *e.g.*, phosphorylation patterns.

10 The activity of the fusion polypeptide is partly determined by its affinity to a binding partner (*e.g.*, receptor or ligand). The affinity of the trimerized molecules for their respective binding partner can be measured using biospecific interaction analysis (BIA), which is a biosensor, *i.e.*, an instrument that combines a biological recognition mechanism with a sensing device or transducer. An exemplary biosensor is BIOcoreTM 15 (Pharmacia). This uses the optical phenomenon surface plasmon resonance to monitor the interaction between two biological molecules. Molecule pairs having affinity constants in the range of 10^5 to 10^{10} M^{-1} , and association rate constants in the range of 10^3 to $10^6 \text{ M}^{-1}\text{s}^{-1}$ are suited for this method.

20 It is also contemplated that, as trimers (or higher order multimers) have more binding sites for their binding partner than dimers or monomers, the multimerized polypeptides of the invention will also have higher avidity for binding partners than will monomers or dimers (or lower order multimers). This higher degree of avidity increases the specific binding of the multimers to their binding partners. As such, in one embodiment, it is contemplated that the polypeptides of the invention can be linked to 25 heterologous therapeutic molecules for high efficiency delivery to target cells expressing a binding partner. Examples of heterologous molecules that can be linked include, but are not limited to, radioactive moieties, *e.g.*, I^{125} , Y^{90} , and/or polypeptide toxins, *e.g.*, ricin, botulism toxin. The linkage can be through standard cross linking techniques well known in the art.

Pharmaceutical Preparations and Methods of Administration

The polypeptides of the invention can be formulated as compounds suitable for administration to a patient in need of treatment. Such compounds are useful in treating immune related disorders and/or in increasing the stimulation of an otherwise normal immune response. A therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms of, for example, immunodeficiency or inflammatory conditions or diseases. Furthermore, when a polypeptide of the invention is co-administered with another therapeutic agent, doses are modified according to any interactions that may occur between the therapeutic agents.

10

Effective Dose

Toxicity and therapeutic efficacy of compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose 15 therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50 /ED50. Compounds which exhibit large therapeutic indices are preferred.

While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in 20 order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies 25 preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell 30 culture prior to administration to a patient.

When another therapeutic is administered in combination with the polypeptides of the invention (coadministration), the polypeptides of the invention can be delivered either

prior to, simultaneous with, or after delivery of the second therapeutic. Simultaneous administration encompasses mixing the polypeptides of the invention with the second therapeutic prior to administration to the patient, or administration to the patient in separate infusions, albeit at the same time. It is also contemplated that the dose of the

5 second therapeutic should be consistent with established therapeutic ranges, however, should there can be an increase in effectiveness of the therapeutic when used in combination with a polypeptides of the invention that is greater than the sum of either alone there is synergy. Thus, in the case of synergy, it will be understood that doses can be decreased relative to recommended ranges in light of enhanced effectiveness.

10 In one embodiment of the invention, a polypeptide of the invention is administered one time per week to treat the various medical disorders disclosed herein, in another embodiment is administered at least two times per week, and in another embodiment is administered at least once per day. An adult patient is a person who is 18 years of age or older. If injected, the effective amount, per adult dose, of a polypeptide of the invention ranges from about 1-500 mg/m², or from about 1-200 mg/m², or from about 15 1-40 mg/m² or about 5-25 mg/m². Alternatively, a flat dose may be administered, whose amount may range from 2-500 mg/dose, 2-100 mg/dose or from about 10-80 mg/dose. If the dose is to be administered more than one time per week, an exemplary dose range is the same as the foregoing described dose ranges or lower. Preferably, polypeptides of the

15 invention are administered two or more times per week at a per dose range of 25-100 mg/dose.

20

In one embodiment of the invention, the various indications described below are treated by administering a preparation acceptable for injection containing a polypeptide of the invention at 80-100 mg/dose, or alternatively, containing 80 mg per dose. The dose 25 can be administered at biweekly, weekly doses, or separated by several weeks (for example 2 to 8).

If a route of administration of the polypeptides of the invention other than injection is used, the dose is appropriately adjusted in accord with standard medical practices. For example, if the route of administration is inhalation, dosing may be one to 30 seven times per week at dose ranges from 10 mg/dose to 50 mg per dose.

In many instances, an improvement in a patient's condition will be obtained by injecting a dose of up to about 100 mg of the polypeptides of the invention one to three

times per week over a period of at least three weeks, though treatment for longer periods may be necessary to induce the desired degree of improvement. For incurable chronic conditions, for example, patients with bone marrow failure caused by a genetic disorder, the regimen may be continued indefinitely.

5 For pediatric patients (ages 4-17), a suitable regimen involves the subcutaneous injection of 0.4 mg/kg to 5 mg/kg of a the polypeptides of the invention, administered by subcutaneous injection one or more times per week.

Formulations and Use

10 Pharmaceutical compositions for use of the compositions of the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or buccal, parenteral or rectal administration.

15 For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

25 The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated for injection. Such formulations are typically stored as aqueous solutions that 30 can be frozen and thawed, but can be also be prepared as lyophilized samples for extended storage. These formulations are frequently presented in a solution that is isotonic with human blood, namely, about 150 mM and buffered. Common buffers

include sodium phosphate and sodium acetate and the pH range can be from 1 to 14, but is more typically around 4.5 to 6. These formulations also can have a polyol (e.g., sorbitol, trehalose, sucrose, etc.) and a surfactant (e.g., polysorbate, Tween 80, etc.) and do not require sodium chloride to be isotonic in solution.

5 The polypeptides of the invention can also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly 10 soluble derivatives, for example, as a sparingly soluble salt.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

15

EXAMPLES

Cloning

Constructs were made by linking three different nucleic acids: 1) the receptor binding domain (RBD) of human CD40L (TNFSF5) as a 0.4kb Xba1-Not1 previously 20 fused to a CD40L (TNFSF5)194W deletion as described in Morris et al. (1999, J. Biol. Chem., 274:418-423); 2) the scavenger receptor trimerization sequence AvrII-Xba1 fragment generated as described below; 3) and the 5.6 kb Spe1- Not1 fragment consisting of the pSMAg expression vector containing the signal sequences and the transcriptional promoter. The resulting nucleic acids are depicted in SEQ ID NOs:5 and 7.

25 The AvrII-Xba1 fragment consisting of the 7 heptad repeat from the scavenger receptor coding sequence were generated through hybridization and ligation of two sets of synthetic oligonucleotides shown in Figure 1 (SR oligo sequences). The oligonucleotide sequence was designed to contain AvrII restriction site overhang at the 5' end and the Xba I restriction site overhang (compatible sequence) at the 3'end of the synthetic 30 scavenger receptor fragment. The XbaI site is TCTAGA, the AvrII restriction site is C/CTAGG and the SpeI restriction site is A/CTAGT. Ligation of Spe1 to AvrII generates

the sequence ACTAGG encoding amino acids threonine and arginine respectively (single amino acid letter code T and R).

Oligos 33 (SEQ ID NO:2) and 35 (SEQ ID NO:4) were phosphorylated using T4 polynucleotide kinase and ATP at 37°C for 1hour. The appropriate oligonucleotide 5 preparations were mixed together in two separate reaction vessels (eppendorf tubes) at 2 µg/ml concentration and annealed by heating each oligonucleotide pair to 95°C for 2 minutes and then held at 65°C for 3 minutes and allowed to cool gradually to room temperature (25°C) over 45 minutes. Oligo 32 (SEQ ID NO:3) was annealed to complementary oligo 35 and Oligo 33 was annealed to complementary oligo 34 (SEQ ID 10 NO:1). The two sets of reactions were mixed together and ligated for 1 hour using DNA Ligase. The ligation reaction was analyzed using preparative 3% Nusieve® agarose gel electrophoresis and the approximately 150 basepairs fragment corresponding to the scavenger receptor AvrII/XbaI fragment was visualized and isolated from the gel.

These nucleic acids were cloned upstream (*i.e.*, N-terminal end) of the receptor 15 binding domain (RBD) of CD40L (TNFSF5) by ligating to an XbaI/NotI fragment containing the CD40L (TNFSF5) RBD and a Not1/SpeI fragment containing the pSMAG vector and the signal sequence. These scavenger receptor nucleic acids replaced the nucleic acids encoding the mutein leucine zipper that were previously used to trimerize/ 20 stabilize the trimers of soluble CD40L (TNFSF5). The expression vector pSMAG used for these constructs contained the transcriptional promoter and either the IL2 signal sequence or the human growth hormone (GH) signal sequence to enable secretion of CD40L (TNFSF5).

The nucleic acid of the final constructs was analyzed on an automated sequencer. Sequence from the signal sequence through the junction of the RBD of CD40L (TNFSF5) 25 was obtained to confirm correct ligation. Figure 2A depicts a fusion polypeptide of the invention where amino acids 1 to 24 are the IL2 signal peptide, amino acids 25 to 39 are linker sequences, amino acids 40 to 88 are the trimerization domain, amino acids 89 to 95 are linker sequences and amino acids 96 to 244 are the CD40L (TNFSF5) 194W deletion sequences and Figure 2B depicts a fusion polypeptide of the invention where amino acids 30 1 to 25 are the IL2 signal peptide, amino acids 26 to 29 are linker sequences, amino acids 30 to 78 are the trimerization domain, amino acids 79 to 85 are linker sequences and amino acids 86 to 234 are the CD40L (TNFSF5) 194W deletion sequences.

Expression

COS cells were transfected with plasmid DNA with 2 μ g in each well in a 6 well transfection vessel and the growth / conditioned media was harvested after 3 days and analyzed on SDS PAGE western blots using a polyclonal anti CD40L (TNFSF5) antibody. The resulting western blot, shown in Figure 3, demonstrates that both isoleucine zipper CD40L (TNFSF5) (Morris et al., (1999) J. Biol. Chem., 274:418-423) and the two forms of the scavenger receptor (SR)-CD40L (TNFSF5), described above, are expressed and secreted. Lanes 1, 3 and 5 contain harvest supernatant at 1:10 dilution and lanes 2, 4 and 6 contain supernatant at 1:30 dilution. Lanes contain harvest supernatant from cells transfected as follows: lanes 1 and 2 contain isoleucine zipper CD40L (TNFSF5) cDNA, lanes 4 and 6 contain growth hormone signal sequence linked to the scavenger receptor trimerization domain-CD40L (TNFSF5) (GH-SR-CD40L), lanes 5 and 6 contain IL2 signal sequence linked to the scavenger receptor trimerization domain-CD40L (TNFSF5) (IL2-SR-CD40L).

15 Bioactivity

The transfection harvest media was analyzed for bioactivity in a B cell proliferation bioassay as described by Morris et al. (1999, J. Biol. Chem., 274:418-423). Costimulation of human blood B cell proliferation was assessed by culturing T-cell depleted PBMC (E) in round bottom 96 well microtiter plates (1×10^5 cells in 200 μ l) for 4 days in the presence of a titration of huCD40L (TNFSF5). Cells were pulsed with tritiated thymidine (91 μ ci/well) for the final 18 hr culture period. Cells cultured with 1 μ g/ml of isoleucine zipper CD40L (TNFSF5) were included as a positive control. Control cells were included as negative control. B cells are the only cells in the E prep that will proliferate in response to CD40L (TNFSF5). The results demonstrate that transfection supernatants containing the scavenger receptor trimerization domain fused to RBD of CD40L (TNFSF5), with the growth hormone signal sequence, are about as active as the leucine zipper form of the CD40L (TNFSF5).

Equivalents and References

30 The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of

the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

5 All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference.

CLAIMS

What is claimed is:

1. A fusion polypeptide comprising a first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID NO:10, wherein x is 110 to 173 and y is 179 to 270, fused to a second heterologous polypeptide, and wherein the fusion polypeptide is capable of forming a trimer.
2. A fusion polypeptide comprising a first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID NO:10, wherein x is 110 to 173 and y is 179 to 270 with at least one substitution of an amino acid, wherein the first polypeptide is at least 80% identical to the polypeptide depicted in SEQ ID NO:10 and the ability to trimerize is retained, and wherein said first polypeptide is fused to a second heterologous polypeptide.
3. The fusion polypeptide of claim 1, wherein the first polypeptide consists of amino acids 154 to 203 of the polypeptide depicted in SEQ ID NO:10.
4. The fusion polypeptide of claim 1, 2 or 3, wherein the second polypeptide is a soluble portion of a tumor necrosis factor receptor super family (TNFRSF).
5. The fusion polypeptide of claim 4, wherein the second polypeptide is a soluble portion of a tumor necrosis factor super family (TNFSF) ligand.
6. The fusion polypeptide of claim 5, wherein the second polypeptide is a soluble portion of a polypeptide selected from the group consisting of TNFRSF1A, TNFRSF1B, TNFRSF3, TNFRSF4, TNFRSF5, TNFRSF6, TNFRSF6B, TNFRSF7, TNFRSF8, TNFRSF9, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF11B, TNFRSF12, TNFRSF12L, TNFRSF13, TNFSF13B,

TNFRSF14, TNFRSF15, NFRSF16, TNFRSF17, TNFRSF18, TNFRSF19, and TNFRSF20.

7. The fusion polypeptide of claim 6, wherein the polypeptide is capable of inhibiting signaling of a tumor necrosis family receptor super family signaling.

8. The fusion polypeptide of claim 7, wherein said first and second polypeptides of said fusion polypeptide are encoded by nucleic acids derived from a human.

9. The fusion polypeptide of claim 8, wherein said fusion polypeptide is non-immunogenic.

10. The fusion polypeptide of claim 5, wherein the second polypeptide is a soluble portion of a polypeptide selected from the group consisting of TNFSF1, TNFSF2, TNFSF3, TNFSF4, TNFSF5, TNFSF6, TNFSF7, TNFSF8, TNFSF9, TNFSF10, TNFSF11, TNFSF12, TNFSF13, TNFSF14, TNFSF15, TNFSF16, TNFSF17, TNFSF18, TNFSF19, and TNFSF20.

11. The fusion polypeptide of claim 10, wherein tumor necrosis family receptor super family signaling is enhanced.

12. The fusion polypeptide of claim 11, wherein said first and second polypeptides of said fusion polypeptide are encoded by nucleic acids derived from a human.

13. The fusion polypeptide of claim 12, wherein said fusion polypeptide is capable of forming a multimer of a trimer.

14. The fusion polypeptide of claim 13, wherein the second heterologous polypeptide comprises the amino acids depicted as amino acids 96 to 244 of SEQ ID NO:6.

15. A nucleic acid encoding the polypeptide of any one of claims 1, 2 or 3.

16. A host cell comprising a nucleic acid of claim 15, wherein said nucleic acid is operably linked to a heterologous control element.

17. A host cell transfected with a nucleic acid according to claim 15.

18. A method of producing a polypeptide encoded by the nucleic acid of claim 15, comprising the steps of growing a host cell transfected with said nucleic acid in conditions favorable for expression of the polypeptide, and isolating said polypeptide.

19. A recombinant vector comprising the nucleic acid of claim 15.

20. A method of constructing a recombinant expression vector comprising the steps of linking a first nucleic acid comprising nucleotides x to y of the nucleic acid depicted in SEQ ID NO:9, wherein x is 331 to 508, and y is 546 to 808, and a second nucleic acid encoding a heterologous polypeptide to the first nucleic acid into a compatible cloning site of an expression vector, followed by amplifying and isolating said recombinant expression vector.

21. The method of claim 20, wherein the second nucleic acid encodes a soluble portion of a polypeptide selected from the group consisting of TNFSF1, TNFRSF1A, TNFSF2, TNFRSF1B, TNFSF3, TNFRSF3, TNFSF4, TNFRSF4, TNFSF5, TNFRSF5, TNFSF6, TNFRSF6, TNFRSF6B, TNFSF7, TNFRSF7, TNFSF8, TNFRSF8, TNFSF9, TNFRSF9, TNFSF10, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFSF11, TNFRSF11A, TNFRSF11B, TNFSF12, TNFRSF12, TNFRSF12L, TNFSF13, TNFRSF13, TNFSF13B, TNFSF14, TNFRSF14, TNFSF15,

TNFRSF15, TNFSF16, NFRSF16, TNFSF17, TNFRSF17, TNFSF18, TNFRSF18,
TNFSF19, TNFRSF19, TNFSF20, and TNFRSF20.

Figure 1**SR L2 (34)**

CTAGAGCTCCTGGTGAAGATTGGATTTGCCATTCAAGATTTCTATGTTGAGC
TGCAAATCAAGCAATGTGGTATTCAAA

SR U2 (33)

AGTCCTAATAAGTTGAATACCACTTGCTTGATTGCAGCTCAACATAGAA
AATCTGAATGGCAAAATCCAATCTCACCCAGGAGCT

SR U1 (32)

CTAGGTCTGACATTCTCTGCAGCTAAGTACCTGTTTCCTCAGTCCAGGGA
CATGGGAATGCAATAGATGAAATCTCCA

SR L1 (35)

CTTATTAAGGACTTGGAGATTCATCTATTGCATTCCATGCCCCTGGACTGA
GGAAAACAAGGTACTTAGCTGCAGAAGAATGTCAGAC

CTAGGTCTGACATTCTCTGCAGCTAAGTACCTGTTTCCTCAGTCCAGGGA
CATGGGAATGCAATAGATGAAATCTCCAAGTCCCTAATAAGTTGAATACCA
CATTGCTGATTGCAGCTCAACATAGAAAATCTGAATGGCAAAATCCAATCT
TCACCAGGAGCTCTAG

Figure 2A

1/1 31/11
 atg gcc ctg tgg atc gac agg atg caa ctc ctg tct tgc att gca cta agt ctt gca ctt
 M A L W I D R M Q L L S C I A L S L A L
 61/21 91/31
 gtc aca aac agt gca cct act tca agt tct aca aag aaa aca cag cta act agg tct GAC
 V T N S A P T S S S T K K T Q L T R S D
 121/41 151/51
 ATT CTT CTG CAG CTA AGT ACC TTG TTT TCC TCA GTC CAG GGA CAT GGG AAT GCA ATA GAT
 I L L Q L S T L F S S V Q G H G N A I D
 181/61 211/71
 GAA ATC TCC AAG TCC TTA ATA AGT TTG AAT ACC ACA TTG CTT GAT TTG CAG CTC AAC ATA
 E I S K S L I S L N T T L L D L Q L N I
 241/81 271/91
 GAA AAT CTG AAT GGC AAA ATC CAA tct tca cca gga gct cta gaa ATG CAA AAA GGT GAT
 E N L N G K I Q S S P G A L E M Q K G D
 301/101 331/111
 CAG AAT CCT CAA ATT GCG GCA CAT GTC ATA AGT GAG GCC AGC AGT AAA ACA ACA TCT GTG
 Q N P Q I A A H V I S E A S S K T T S V
 361/121 391/131
 TTA CAG TGG GCT GAA AAA GGA TAC TAC ACC ATG AGC AAC AAC TTG GTA ACC CTC GAA AAT
 L Q W A E K G Y Y T M S N N L V T L E N
 421/141 451/151
 GGG AAA CAG CTG acc GTT AAA AGA CAA GGA CTC TAT TAT ATC TAT GGC CAA GTC ACC TTC
 G K Q L T V K R Q G L Y Y I Y A Q V T F
 481/161 511/171
 TGT TCC AAT CGG GAA GCT TCG AGT CAA GCT CCA TTT ATA GCC AGC CTC TGG CTA AAG TCC
 C S N R E A S S Q A P F I A S L W L K S
 541/181 571/191
 CCC GGT AGA TTC GAG AGA ATC TTA CTC AGA GCT GCA AAT ACC CAC AGT TCC GCC AAA CCT
 P G R F E R I L L R A A N T H S S A K P
 601/201 631/211
 TGC GGG CAA CAA TCC ATT CAC TTG GGA GGA GTA TTT GAA TTG CAA CCA GGT GCT TGG GTG
 C G Q Q S I H L G G V F E L Q P G A S V
 661/221 691/231
 TTT GTC AAT GTG ACT GAT CCA AGC CAA GTG AGC CAT GGC ACT GGC TTC ACG TCC TTT GGC
 F V N V T D P S Q V S H G T G F T S F G
 721/241
 TTA CTC AAA CTC TGA GcG GCc gc
 L L K L * A A

Figure 2B

1/1 31/11
 atg gct aca ggc tcc cgg acg tcc ctg ctc ctg gct ttt ggc ctg ctc tgc ctg ccc tgg
 M A T G S R T S L L L A F G L L C L P W
 61/21 91/31
 ctt caa gag ggc agt gca act agg tct GAC ATT CTT CTG CAG CTA AGT ACC TTG TTT TCC
 L Q E G S A T R S D I L L Q L S T L F S
 121/41 151/51
 TCA GTC CAG GGA CAT GGG AAT GCA ATA GAT GAA ATC TCC AAG TCC TTA ATA AGT TTG AAT
 S V Q G H G N A I D E I S K S L I S L N
 181/61 211/71
 ACC ACA TTG CTT GAT TTG CAG CTC AAC ATA GAA AAT CTG AAT GGC AAA ATC CAA tct tca
 T T L L D L Q L N I E N L N G K I Q S S
 241/81 271/91
 cca gga gct cta gaa ATG CAA AAA GGT GAT CAG AAT CCT CAA ATT GCG GCA CAT GTC ATA
 P G A L E M Q K G D Q N P Q I A A H V I
 301/101 331/111
 AGT GAG GCC AGC AGT AAA ACA ACA TCT GTG TTA CAG TGG GCT GAA AAA GGA TAC TAC ACC
 S E A S S K T T S V L Q W A E K G Y Y T
 361/121 391/131
 ATG AGC AAC AAC TTG GTA ACC CTG GAA AAT GGG AAA CAG CTG aCC GTT AAA AGA CAA GGA
 M S N N L V T L E N G K Q L T V K R Q G
 421/141 451/151
 CTC TAT TAT ATC TAT GCC CAA GTC ACC TTC TGT TCC AAT CGG GAA GCT TCG AGT CAA GCT
 L Y Y I Y A Q V T F C S N R E A S S Q A
 481/161 511/171
 CCA TTT ATA GCC AGC CTC TGG CTA AAG TCC CCC GGT AGA TTC GAG AGA ATC TTA CTC AGA
 P F I A S L W L K S P G R F E R I L L R
 541/181 571/191
 GCT GCA AAT ACC CAC AGT TCC GCC AAA CCT TGC GGG CAA CAA TCC ATT CAC TTG GGA GGA
 A A N T H S S A K P C G Q Q S I H L G G
 601/201 631/211
 GTA TTT GAA TTG CAA CCA GGT GCT TGG GTG TTT GTC AAT GTG ACT GAT CCA AGC CAA GTG
 V F E L Q P G A S V F V N V T D P S Q V
 661/221 691/231
 AGC CAT GGC ACT GGC TTC ACG TCC TTT GGC TTA CTC AAA CTC TGA GCG GCG gc
 S H G T G F T S F G L L K L * A A


Figure 3

Figure 4

Query : ATGGAGCAGTGGGATCACTTCAACAATCAACAGGAGGACACTGATAGCTG	10 20 30 40 50
Framel : M E Q W D H F H N Q Q B D T D S C	----- ----- ----- ----- -----
Query : CTCCGAATCTGTGAAATTGATGCTCGCTCAATGACAGCTTGCTTCCTC	60 70 80 90 100
Framel : S E S V K F D A R S M T A L L P P	----- ----- ----- ----- -----
Query : CGAATCCTAAAACAGCCCTTCCCTCAAGAGAAACTGAAGTCCTCAAA	110 120 130 140 150
Framel : N P K N S P S L Q E K L K S F K	----- ----- ----- ----- -----
Query : GCTGCACTGATTGCCCTTACCTCCTCGTGTTCAGTTCTCATCCCTCT	160 170 180 190 200
Framel : A A L I A L Y L L V F A V L I P L	----- ----- ----- ----- -----
Query : CATTGGAATAGTGGCAGCTCAAACCTCTGAAGTGGAAACGAAGAATTGCT	210 220 230 240 250
Framel : I G I V A A Q L L K W E T K N C S	----- ----- ----- ----- -----
Query : CAGTTAGTTCAACTAATGCAAATGATATAACTCAAAGTCTCACGGGAAAA	260 270 280 290 300
Framel : V S S T N A N D I T Q S L T G K	----- ----- ----- ----- -----
Query : GGAAATGACAGCGAAGAGGAAATGAGATTCAAGAAGTCTTATGGAACA	310 320 330 340 350
Framel : G N D S E E E M R F Q E V F M E H	----- ----- ----- ----- -----
Query : CATGAGCAACATGGAGAAGAGAATCCAGCATATTAGACATGGAAGCCA	360 370 380 390 400
Framel : M S N M E K R I Q H I L D M E A N	----- ----- ----- ----- -----
Query : ACCTCATGGACACAGAGCATTCCAAAATTCAGCATGACAACGTGATCAA	410 420 430 440 450
Framel : L M D T E H F Q N F S M T T D Q	----- ----- ----- ----- -----
Query : AGATTTAATGACATTCTCTGCAGCTAAGTACCTGTTCCCTCAGTCCA	460 470 480 490 500
	----- ----- ----- ----- -----

Frame1 : R F N D I L L Q L S T L F S S V Q

510 520 530 540 550

Query : GGGACATGGGAATGCAATAGATGAAATCTCCAAGTCCTTAATAAGTTGA

Frame1 : G H G N A I D E I S K S L I S L N

560 570 580 590 600

Query : ATACCACATTGCTTGAATTGCAGCTAACATAGAAAATCTGAATGGCAAA

Frame1 : T T L L D L Q L N I E N L N G K

610 620 630 640 650

Query : ATCCAAGAGAATACCTTCAACAAACAAGAGGAAATCAGTAAATTAGAGGA

Frame1 : I Q E N T F K Q Q E E I S K L E E

660 670 680 690 700

Query : GCGTGTTCACATGTATCAGCAGAAATTATGGCTATGAAAGAAGAACAG

Frame1 : R V Y N V S A E I M A M K E E Q V

710 720 730 740 750

Query : TGCAATTGGAACAGGAAATAAGGAGAAGTGAAGTACTGAATAACATC

Frame1 : H L E Q E I K G E V K V L N N I

760 770 780 790 800

Query : ACTAATGATCTCAGACTGAAAGATTGGAACATTCTCAGACCTTGAGAAA

Frame1 : T N D L R L K D W E H S Q T L R N

810 820 830 840 850

Query : TATCACTTTAACCTCAAGGTCTCCTGGACCCCCGGTGAAAAGGAGATC

Frame1 : I T L I Q G P P G P P G E K G D R

860 870 880 890 900

Query : GAGGTCCCCTGGAGAAAGTGGTCCACGAGGATTCCAGGTCCAATAGGT

Frame1 : G P T G E S G P R G F P G P I G

910 920 930 940 950

Query : CCTCCGGGTCTAAAGGTGATCGGGAGCAATTGGCTTCCTGGAAAGTCG

Frame1 : P P G L K G D R G A I G F P G S R

960 970 980 990 1000

Query : AGGAATCCCAGGATATGCCGAAGGCCAGGAAATTCTGGACCAAAAGGCC

Frame1 : G L P G Y A G R P G N S G P K G Q

1010 1020 1030 1040 1050
-----|-----|-----|-----|
Query : AGAAAGGGAAAAGGGGAGTGGAAACACATTAAGACAGTACAACACTCACT
Frame1 : K G E K G S G N T L R P V Q L T

1060 1070
-----|-----|
Query : GATCATATTAGGGCAGGGCCCTCTTAA
Frame1 : D H I R A G P S *

Seq List 3398.ST25.txt
SEQUENCE LISTING

<110> Reddy, Pranhitha

<120> Trimeric Recombinant Polypeptides

<130> 3398-W0

<160> 10

<170> PatentIn version 3.1

<210> 1

<211> 80

<212> DNA

<213> Homo sapiens

<400> 1

ctagagctcc tggtaagat tggatttgc cattcagatt ttctatgttg agctgcaa 60

caagcaatgt ggtattcaaa 80

<210> 2

<211> 89

<212> DNA

<213> Homo sapiens

<400> 2

agtcccttaat aagttgaat accacattgc ttgatttgca gctcaacata gaaaatctg 60

atggcaaaat ccaatcttca ccaggagct 89

<210> 3

<211> 81

<212> DNA

<213> Homo sapiens

<400> 3

ctaggctga cattttctg cagctaagta ctttggat ctcagtcgg 60

atgcaataga tgaaatctcc a 81

<210> 4

<211> 90

<212> DNA

<213> Homo sapiens

<400> 4

cttattaagg acttggagat ttcatctatt gcattccat gtccctggac tgaggaaa 60

aaggtaatcc gctgcagaag aatgtcagac 90

<210> 5

<211> 1077

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

Seq List 3398.ST25.txt

<222> (1)..(1077)
<223>

<400> 5 atg gag cag tgg gat cac ttt cac aat caa cag gag gac act gat agc Met Glu Gln Trp Asp His Phe His Asn Gln Gln Glu Asp Thr Asp Ser 1 5 10 15	48
tgc tcc gaa tct gtg aaa ttt gat gct cgc tca atg aca gct ttg ctt Cys Ser Glu Ser Val Lys Phe Asp Ala Arg Ser Met Thr Ala Leu Leu 20 25 30	96
cct ccg aat cct aaa aac agc cct tcc ctt caa gag aaa ctg aag tcc Pro Pro Asn Pro Lys Asn Ser Pro Ser Leu Gln Glu Lys Leu Lys Ser 35 40 45	144
ttc aaa gct gca ctg att gcc ctt tac ctc ctc gtg ttt gca gtt ctc Phe Lys Ala Ala Leu Ile Ala Leu Tyr Leu Leu Val Phe Ala Val Leu 50 55 60	192
atc cct ctc att gga ata gtg gca gct caa ctc ctg aag tgg gaa acg Ile Pro Leu Ile Gly Ile Val Ala Ala Gln Leu Leu Lys Trp Glu Thr 65 70 75 80	240
aag aat tgc tca gtt agt tca act aat gca aat gat ata act caa agt Lys Asn Cys Ser Val Ser Ser Thr Asn Ala Asn Asp Ile Thr Gln Ser 85 90 95	288
ctc acg gga aaa gga aat gac agc gaa gag gaa atg aga ttt caa gaa Leu Thr Gly Lys Gly Asn Asp Ser Glu Glu Glu Met Arg Phe Gln Glu 100 105 110	336
gtc ttt atg gaa cac atg agc aac atg gag aag aga atc cag cat att Val Phe Met Glu His Met Ser Asn Met Glu Lys Arg Ile Gln His Ile 115 120 125	384
tta gac atg gaa gcc aac ctc atg gac aca gag cat ttc caa aat ttc Leu Asp Met Glu Ala Asn Leu Met Asp Thr Glu His Phe Gln Asn Phe 130 135 140	432
agc atg aca act gat caa aga ttt aat gac att ctt ctg cag cta agt Ser Met Thr Thr Asp Gln Arg Phe Asn Asp Ile Leu Leu Gln Leu Ser 145 150 155 160	480
acc ttg ttt tcc tca gtc cag gga cat ggg aat gca ata gat gaa atc Thr Leu Phe Ser Ser Val Gln Gly His Gly Asn Ala Ile Asp Glu Ile 165 170 175	528
tcc aag tcc tta ata agt ttg aat acc aca ttg ctt gat ttg cag ctc Ser Lys Ser Leu Ile Ser Leu Asn Thr Thr Leu Leu Asp Leu Gln Leu 180 185 190	576
aac ata gaa aat ctg aat ggc aaa atc caa gag aat acc ttc aaa caa Asn Ile Glu Asn Leu Asn Gly Lys Ile Gln Glu Asn Thr Phe Lys Gln 195 200 205	624
caa gag gaa atc agt aaa tta gag gag cgt gtt tac aat gta tca gca Gln Glu Glu Ile Ser Lys Leu Glu Glu Arg Val Tyr Asn Val Ser Ala 210 215 220	672
gaa att atg gct atg aaa gaa gaa caa gtg cat ttg gaa cag gaa ata Glu Ile Met Ala Met Lys Glu Glu Gln Val His Leu Glu Gln Glu Ile 225 230 235 240	720

Seq List 3398.ST25.txt

aaa gga gaa gtg aaa gta ctg aat aac atc act aat gat ctc aga ctg Lys Gly Glu Val Lys Val Leu Asn Asn Ile Thr Asn Asp Leu Arg Leu 245 250 255	768
aaa gat tgg gaa cat tct cag acc ttg aga aat atc act tta att caa Lys Asp Trp Glu His Ser Gln Thr Leu Arg Asn Ile Thr Leu Ile Gln 260 265 270	816
ggt cct cct gga ccc ccg ggt gaa aaa gga gat cga ggt ccc act gga Gly Pro Pro Gly Pro Pro Gly Glu Lys Gly Asp Arg Gly Pro Thr Gly 275 280 285	864
gaa agt ggt cca cga gga ttt cca ggt cca ata ggt cct ccg ggt ctt Glu Ser Gly Pro Arg Gly Phe Pro Gly Pro Ile Gly Pro Pro Gly Leu 290 295 300	912
aaa ggt gat cgg gga gca att ggc ttt cct gga agt cga gga ctc cca Lys Gly Asp Arg Gly Ala Ile Gly Phe Pro Gly Ser Arg Gly Leu Pro 305 310 315 320	960
gga tat gcc gga agg cca gga aat tct gga cca aaa ggc cag aaa ggg Gly Tyr Ala Gly Arg Pro Gly Asn Ser Gly Pro Lys Gly Gln Lys Gly 325 330 335	1008
gaa aag ggg agt gga aac aca tta aga cca gta caa ctc act gat cat Glu Lys Gly Ser Gly Asn Thr Leu Arg Pro Val Gln Leu Thr Asp His 340 345 350	1056
att agg gca ggg ccc tct taa Ile Arg Ala Gly Pro Ser 355	1077

<210> 6
<211> 358
<212> PRT
<213> Homo sapiens

<400> 6

Met Glu Gln Trp Asp His Phe His Asn Gln Gln Glu Asp Thr Asp Ser
1 5 10 15

Cys Ser Glu Ser Val Lys Phe Asp Ala Arg Ser Met Thr Ala Leu Leu
20 25 30

Pro Pro Asn Pro Lys Asn Ser Pro Ser Leu Gln Glu Lys Leu Lys Ser
35 40 45

Phe Lys Ala Ala Leu Ile Ala Leu Tyr Leu Leu Val Phe Ala Val Leu
50 55 60

Ile Pro Leu Ile Gly Ile Val Ala Ala Gln Leu Leu Lys Trp Glu Thr
65 70 75 80

Lys Asn Cys Ser Val Ser Ser Thr Asn Ala Asn Asp Ile Thr Gln Ser
85 90 95

Seq List 3398.ST25.txt

Leu Thr Gly Lys Gly Asn Asp Ser Glu Glu Glu Met Arg Phe Gln Glu
100 105 110

Val Phe Met Glu His Met Ser Asn Met Glu Lys Arg Ile Gln His Ile
115 120 125

Leu Asp Met Glu Ala Asn Leu Met Asp Thr Glu His Phe Gln Asn Phe
130 135 140

Ser Met Thr Thr Asp Gln Arg Phe Asn Asp Ile Leu Leu Gln Leu Ser
145 150 155 160

Thr Leu Phe Ser Ser Val Gln Gly His Gly Asn Ala Ile Asp Glu Ile
165 170 175

Ser Lys Ser Leu Ile Ser Leu Asn Thr Thr Leu Leu Asp Leu Gln Leu
180 185 190

Asn Ile Glu Asn Leu Asn Gly Lys Ile Gln Glu Asn Thr Phe Lys Gln
195 200 205

Gln Glu Glu Ile Ser Lys Leu Glu Glu Arg Val Tyr Asn Val Ser Ala
210 215 220

Glu Ile Met Ala Met Lys Glu Glu Gln Val His Leu Glu Gln Glu Ile
225 230 235 240

Lys Gly Glu Val Lys Val Leu Asn Asn Ile Thr Asn Asp Leu Arg Leu
245 250 255

Lys Asp Trp Glu His Ser Gln Thr Leu Arg Asn Ile Thr Leu Ile Gln
260 265 270

Gly Pro Pro Gly Pro Pro Gly Glu Lys Gly Asp Arg Gly Pro Thr Gly
275 280 285

Glu Ser Gly Pro Arg Gly Phe Pro Gly Pro Ile Gly Pro Pro Gly Leu
290 295 300

Lys Gly Asp Arg Gly Ala Ile Gly Phe Pro Gly Ser Arg Gly Leu Pro
305 310 315 320

Gly Tyr Ala Gly Arg Pro Gly Asn Ser Gly Pro Lys Gly Gln Lys Gly
325 330 335

Glu Lys Gly Ser Gly Asn Thr Leu Arg Pro Val Gln Leu Thr Asp His

340

Seq List 3398.ST25.txt
345 350Ile Arg Ala Gly Pro Ser
355

<210> 7
<211> 743
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)..(735)
<223>

<400> 7
atg gcc ctg tgg atc gac agg atg caa ctc ctg tct tgc att gca cta 48
Met Ala Leu Trp Ile Asp Arg Met Gln Leu Leu Ser Cys Ile Ala Leu
1 5 10 15
agt ctt gca ctt gtc aca aac agt gca cct act tca agt tct aca aag 96
Ser Leu Ala Leu Val Thr Asn Ser Ala Pro Thr Ser Ser Ser Thr Lys
20 25 30
aaa aca cag cta act agg tct gac att ctt ctg cag cta agt acc ttg 144
Lys Thr Gln Leu Thr Arg Ser Asp Ile Leu Leu Gln Leu Ser Thr Leu
35 40 45
ttt tcc tca gtc cag gga cat ggg aat gca ata gat gaa atc tcc aag 192
Phe Ser Ser Val Gln Gly His Gly Asn Ala Ile Asp Glu Ile Ser Lys
50 55 60
tcc tta ata agt ttg aat acc aca ttg ctt gat ttg cag ctc aac ata 240
Ser Leu Ile Ser Leu Asn Thr Thr Leu Leu Asp Leu Gln Leu Asn Ile
65 70 75 80
gaa aat ctg aat ggc aaa atc caa tct tca cca gga gct cta gaa atg 288
Glu Asn Leu Asn Gly Ile Gln Ser Ser Pro Gly Ala Leu Glu Met
85 90 95
caa aaa ggt gat cag aat cct caa att gcg gca cat gtc ata agt gag 336
Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu
100 105 110
gcc agc agt aaa aca aca tct gtg tta cag tgg gct gaa aaa gga tac 384
Ala Ser Ser Lys Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr
115 120 125
tac acc atg agc aac aac ttg gta acc ctg gaa aat ggg aaa cag ctg 432
Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu
130 135 140
acc gtt aaa aga caa gga ctc tat tat atc tat gcc caa gtc acc ttc 480
Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe
145 150 155 160
tgt tcc aat cgg gaa gct tcg agt caa gct cca ttt ata gcc agc ctc 528
Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu
165 170 175
tgg cta aag tcc ccc ggt aga ttc gag aga atc tta ctc aga gct gca 576

Seq List 3398.ST25.txt

Trp Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala			
180	185	190	
aat acc cac agt tcc gcc aaa cct tgc ggg caa caa tcc att cac ttg			624
Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu			
195	200	205	
gga gga gta ttt gaa ttg caa cca ggt gct tcg gtg ttt gtc aat gtg			672
Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val			
210	215	220	
act gat cca agc caa gtg agc cat ggc act ggc ttc acg tcc ttt ggc			720
Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly			
225	230	235	240
tta ctc aaa ctc tga gcggccgc			743
Leu Leu Lys Leu			

<210> 8

<211> 244

<212> PRT

<213> Homo sapiens

<400> 8

Met Ala Leu Trp Ile Asp Arg Met Gln Leu Leu Ser Cys Ile Ala Leu			
1	5	10	15

Ser Leu Ala Leu Val Thr Asn Ser Ala Pro Thr Ser Ser Thr Lys			
20	25	30	

Lys Thr Gln Leu Thr Arg Ser Asp Ile Leu Leu Gln Leu Ser Thr Leu			
35	40	45	

Phe Ser Ser Val Gln Gly His Gly Asn Ala Ile Asp Glu Ile Ser Lys			
50	55	60	

Ser Leu Ile Ser Leu Asn Thr Thr Leu Leu Asp Leu Gln Leu Asn Ile			
65	70	75	80

Glu Asn Leu Asn Gly Lys Ile Gln Ser Ser Pro Gly Ala Leu Glu Met			
85	90	95	

Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu			
100	105	110	

Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr			
115	120	125	

Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu			
130	135	140	

Seq List 3398,ST25.txt

Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe
145 150 155 160

Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu
165 170 175

Trp Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala
180 185 190

Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu
195 200 205

Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val
210 215 220

Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly
225 230 235 240

Leu Leu Lys Leu

<210> 9
<211> 713
<212> DNA
<213> *Homo sapiens*

<220>
<221> CDS
<222> (1)..(705)
<223>

<400> 9
atg gct aca ggc tcc cg^g acg tcc ctg ctc ctg gct ttt ggc ctg ctc 48
Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu
1 5 10 15

tgc ctg ccc tgg ctt caa gag ggc agt gca act agg tct gac att ctt 96
 Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Thr Arg Ser Asp Ile Leu
 20 25 30

ctg cag cta agt acc ttg ttt tcc tca gtc cag gga cat ggg aat gca 144
 Leu Gln Leu Ser Thr Leu Phe Ser Ser Val Gln Gly His Gly Asn Ala.
 35 40 45

ata gat gaa atc tcc aag tcc tta ata agt ttg aat acc aca ttg ctt 192
 Ile Asp Glu Ile Ser Lys Ser Leu Ile Ser Leu Asn Thr Thr Leu Leu
 50 55 60

gat ttg cag ctc aac ata gaa aat ctg aat ggc aaa atc caa tct tca 240
 Asp Leu Gln Leu Asn Ile Glu Asn Leu Asn Gly Lys Ile Gln Ser Ser
 65 70 75 80

cca gga gct cta gaa atg caa aaa ggt gat cag aat cct caa att gcg 288
 Pro Gly Ala Leu Glu Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala
 85 90 95

Seq List 3398.ST25.txt

gca cat gtc ata agt gag gcc agc agt aaa aca aca tct gtg tta cag Ala His Val Ile Ser Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln 100 105 110	336
tgg gct gaa aaa gga tac tac acc atg agc aac aac ttg gta acc ctg Trp Ala Glu Lys Gly Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu 115 120 125	384
gaa aat ggg aaa cag ctg acc gtt aaa aga caa gga ctc tat tat atc Glu Asn Gly Lys Gln Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile 130 135 140	432
tat gcc caa gtc acc ttc tgt tcc aat cgg gaa gct tcg agt caa gct Tyr Ala Gln Val Thr Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala 145 150 155 160	480
cca ttt ata gcc agc ctc tgg cta aag tcc ccc ggt aga ttc gag aga Pro Phe Ile Ala Ser Leu Trp Leu Lys Ser Pro Gly Arg Phe Glu Arg 165 170 175	528
atc tta ctc aga gct gca aat acc cac agt tcc gcc aaa cct tgc ggg Ile Leu Leu Arg Ala Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly 180 185 190	576
caa caa tcc att cac ttg gga gga gta ttt gaa ttg caa caa ggt gct Gln Gln Ser Ile His Leu Gly Gly Val Phe Glu Leu Gln Gln Gly Ala 195 200 205	624
tcg gtg ttt gtc aat gtg act gat cca agc caa gtg agc cat ggc act Ser Val Phe Val Asn Val Thr Asp Pro Ser Gln Val Ser His Gly Thr 210 215 220	672
ggc ttc acg tcc ttt ggc tta ctc aaa ctc tga gcggccgc Gly Phe Thr Ser Phe Gly Leu Leu Lys Leu 225 230	713
<210> 10	
<211> 234	
<212> PRT	
<213> Homo sapiens	
<400> 10	
Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu 1 5 10 15	
Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Thr Arg Ser Asp Ile Leu 20 25 30	
Leu Gln Leu Ser Thr Leu Phe Ser Ser Val Gln Gly His Gly Asn Ala 35 40 45	
Ile Asp Glu Ile Ser Lys Ser Leu Ile Ser Leu Asn Thr Thr Leu Leu 50 55 60	
Asp Leu Gln Leu Asn Ile Glu Asn Leu Asn Gly Lys Ile Gln Ser Ser 65 70 75 80	

Seq List 3398.ST25.txt

Pro Gly Ala Leu Glu Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala
85 90 95

Ala His Val Ile Ser Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln
100 105 110

Trp Ala Glu Lys Gly Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu
115 120 125

Glu Asn Gly Lys Gln Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile
130 135 140

Tyr Ala Gln Val Thr Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala
145 150 155 160

Pro Phe Ile Ala Ser Leu Trp Leu Lys Ser Pro Gly Arg Phe Glu Arg
165 170 175

Ile Leu Leu Arg Ala Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly
180 185 190

Gln Gln Ser Ile His Leu Gly Gly Val Phe Glu Leu Gln Gln Gly Ala
195 200 205

Ser Val Phe Val Asn Val Thr Asp Pro Ser Gln Val Ser His Gly Thr
210 215 220

Gly Phe Thr Ser Phe Gly Leu Leu Lys Leu
225 230

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number
WO 2003/060072 A3

(51) International Patent Classification⁷: C07K 14/52,
14/525, 14/705, 14/715, 14/725, C12N 5/10, 15/10, 15/12,
15/19, 15/28

(21) International Application Number:
PCT/US2002/040913

(22) International Filing Date:
20 December 2002 (20.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/343,315 21 December 2001 (21.12.2001) US

(71) Applicant (for all designated States except US): IMMUNEX CORPORATION [US/US]; Law Department,
51 University Street, Seattle, WA 98101 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): REDDY, Pranitha
[US/US]; 6811 18th Avenue NE, Seattle, WA 98115 (US).

(74) Agents: ODRE, Steven, M. et al.; Immunex Corporation,
Law Department, 51 University Street, Seattle, WA 98101
(US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
15 January 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2003/060072 A3

(54) Title: RECOMBINANT POLYPEPTIDES

(57) Abstract: The present invention relates, in part, to a polypeptide domain having reduced immunogenicity that is capable of inducing trimers in heterologous polypeptides, fusion polypeptides comprising the trimer inducing domain, nucleic acids encoding the polypeptides of the invention and methods of making and using the same.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/40913

A. CLASSIFICATION OF SUBJECT MATTER																				
IPC(7) : C07K 14/52, 14/525, 14/705, 14/715, 14/725; C12N 5/10, 15/10, 15/12, 15/19, 15/28 US CL : 530/350, 351; 536/23.1, 23.4, 23.5; 435/69.4, 320.1, 325, 252.3, 254.11 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED																				
Minimum documentation searched (classification system followed by classification symbols) U.S. : 530/350, 351; 536/23.1, 23.4, 23.5; 435/69.4, 320.1, 325, 252.3, 254.11																				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X	FANSLOW ET AL. Structural characteristics of CD40 ligand that determine biological function. Seminars in Immunology. 1994, Vol. 6, pages 267-278, especially Figures 1 and 3.	1-3, 15-20 ----- 4-13, 21																		
X ---	MORRIS ET AL. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J. Biol. Chem. 01 January 1999, Vol. 274, No. 1, pages 418-423, especially page 412.	1-3, 15-20 ----- 4-13, 21																		
Y	FRANK ET AL. A distinct seven-residue trigger sequence is indispensable for proper coiled-coil formation of the human macrophage scavenger receptor oligomerization domain. J. Biol. Chem. 21 April 2000, Vol. 275, No. 16, pages 11672-11677, see entire document.	4-13, 21																		
X	US 5,716,805 A (SRINIVASAN ET AL.) 10 February 1998 (10.02.1998), entire document.	1-13, 15-21																		
X ---	US 6,087,329 A (ARMITAGE ET AL.) 11 July 2000 (11.07.2000), entire document, especially TABLE 12.	1-3, 15-20 ----- 4-13, 21																		
<p><input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.</p> <table> <tr> <td>* Special categories of cited documents:</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier application or patent published on or after the international filing date</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
B earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family																		
O document referring to an oral disclosure, use, exhibition or other means																				
P document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 24 October 2003 (24.10.2003)	Date of mailing of the international search report 17 NOV 2003																			
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230	Authorized officer <i>Telicia I. Roberts</i> for Claire M. Kaufman Telephone No. (703)308-0196																			

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/40913

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.: 1-2,4-21 in part because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Please See Continuation Sheet

3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US02/40913

Continuation of Box I Reason 2:

As SEQ ID NO:10 has only 234 amino acids and SEQ ID NO:9 has only 713 nucleotides, any values in the claims exceeding those lengths were unsearchable. Note that values equal to or less than those length were, however, able to be searched.

Continuation of B. FIELDS SEARCHED Item 3:

WEST, GenBank, EMBL, Medline, CaPlus

search terms: macrophage scavenger receptor, TNFRSF?, SR-A, CD40 or CD40L